|Slideshows|August 7, 2018

Schizophrenia and Lifestyle: A Delicate Balance

A meta-analysis exploring factors associated with quality of life in first-episode psychosis provides guidance and take-home points for clinicians.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

ByAntonio Vita, MD, PhD,Gabriele Nibbio, MD, PhD,Stefano Barlati, MD

June 19th 2026

Treating Patients With First-Episode Psychosis: Lessons From McLean OnTrack

ByMichael Murphy, MD, PhD,Allison Nelson-Eliot, LICSW

June 18th 2026

Assessment of Suicide Risk in Individuals With Schizophrenia

ByCarla Kotzé, PhD, MMed, MPhil, FCPsych,Johannes Lodewikus Roos, MD, DSc, MMed, FCPsych

June 17th 2026

Transcranial Direct Current Stimulation to Enhance Brain Activity: Applicability for Schizophrenia

ByTony Cunningham, PhD

June 17th 2026

Consensus on Overcoming Barriers to Long-Acting Injectable Use in Schizophrenia

ByLeighann Forbes, PhD

June 12th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Schizophrenia and Lifestyle: A Delicate Balance

Related Content

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

Treating Patients With First-Episode Psychosis: Lessons From McLean OnTrack

Assessment of Suicide Risk in Individuals With Schizophrenia

Transcranial Direct Current Stimulation to Enhance Brain Activity: Applicability for Schizophrenia

Consensus on Overcoming Barriers to Long-Acting Injectable Use in Schizophrenia

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Sex Differences, Sleep Problems, and Psychological Well-Being in Older Adults

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

Reducing Microsleeps: Oveporexton's Impact on Patient Outcomes

New Data on Alixorexton for Narcolepsy Type 2: Insights From Richard K. Bogan, MD

The Association Between Sleep, Sex Differences, and Mental Health Across the Lifespan